IGFBP6 and metabolic dysfunction-associated steatotic liver disease: In hepatic fibrosis, IGFBP-6 has emerged as a key marker; reduced IGFBP-6 expression is seen in chronic hepatitis C as it progresses to fibrosis, and in NAFLD patients with fibrosis, elevated hepatic IGFBP-6 levels strongly correlate with advanced fibrosis [123,124].